Bioequivalence of Related GelShield < sup > Ⓡ < /sup > Sustained-Release Formulations of Metformin: A Pooled Pharmacokinetic Analysis
Clin Ther. 2024 Apr 29:S0149-2918(24)00077-8. doi: 10.1016/j.clinthera.2024.03.011. Online ahead of print.ABSTRACTPURPOSE: GlucophageⓇ (Merck Healthcare KGaA, Darmstadt, Germany) is the originator brand of metformin hydrochloride, an oral antidiabetic drug. Metformin is recommended in guidelines as first-line treatment of type 2 diabetes mellitus and increasingly in related insulin-resistant conditions, such as prediabetes and polycystic ovary syndrome. The GelShieldⓇ sustained-release formulation tablet of GlucophageⓇ has been improved from the historic version marketed in 2000. Bioequivalence has been demonstrated ...
Source: Clinical Therapeutics - April 30, 2024 Category: Drugs & Pharmacology Authors: Axel Krebs-Brown Kerstin M G Brand Marco A F Nogueira Filho Sumedh Gaikwad Yvonne Schnaars Source Type: research
Effect of surgical volume on short-term outcomes of cytoreductive surgery for advanced-stage ovarian cancer: A population-based study from the Dutch Gynecological Oncology Audit
CONCLUSIONS: Our analyses do not support further centralization of iCRS for advanced-stage OC. High-volume was associated with higher complete pCRS, suggesting either a more accurate selection in these hospitals or a more aggressive approach. The higher completeness rates were at the expense of higher severe complications and prolonged admissions.PMID:38688188 | DOI:10.1016/j.ygyno.2024.04.002 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - April 30, 2024 Category: Cancer & Oncology Authors: M D Algera W J van Driel B F M Slangen M W J M Wouters R F P M Kruitwagen participants of the Dutch Gynecological Oncology Audit Collaborator Group Source Type: research
Deciphering resistance mechanisms and novel strategies to overcome drug resistance in ovarian cancer: a comprehensive review
Oncol Res. 2024 Apr 23;32(5):831-847. doi: 10.32604/or.2024.031006. eCollection 2024.ABSTRACTOvarian cancer is among the most lethal gynecological cancers, primarily due to the lack of specific symptoms leading to an advanced-stage diagnosis and resistance to chemotherapy. Drug resistance (DR) poses the most significant challenge in treating patients with existing drugs. The Food and Drug Administration (FDA) has recently approved three new therapeutic drugs, including two poly (ADP-ribose) polymerase (PARP) inhibitors (olaparib and niraparib) and one vascular endothelial growth factor (VEGF) inhibitor (bevacizumab) for ma...
Source: Oncology Research - April 30, 2024 Category: Cancer & Oncology Authors: Effat Alemzadeh Leila Allahqoli Afrooz Mazidimoradi Esmat Alemzadeh Fahimeh Ghasemi Hamid Salehiniya Ibrahim Alkatout Source Type: research
Clinical and genomic landscape of RAS mutations in gynecologic cancers
CONCLUSION: RAS mutations in gynecologic cancers have a distinct histopathologic distribution and may impact overall survival. PIK3CA, PTEN, and ARID1A are potentially actionable co-alterations. RAS pathway-targeted therapy should be considered.PMID:38687597 | DOI:10.1158/1078-0432.CCR-23-2819 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - April 30, 2024 Category: Cancer & Oncology Authors: Ji Son Yingao Zhang Heather Lin Oriol Mirallas Pablo Alvarez Ballesteros Mirella Nardo Natalie Clark R Tyler Hillman Erick Campbell Vijaykumar Holla Amber M Johnson Amadeo B Biter Ying Yuan Lauren P Cobb David M Gershenson Amir A Jazaeri Karen H Lu Pamela Source Type: research
Expression of human dCTP pyrophosphatase 1 (DCTPP1) and its association with cisplatin resistance characteristics in ovarian cancer
In this study, we aimed to understand the role of DCTPP1 in cancer progression and cisplatin response. Using publicly available databases, we analysed the expression and clinical significance of DCTPP1 in ovarian cancer. Our bioinformatics analysis confirmed that DCTPP1 is significantly overexpressed in ovarian cancer and is closely associated with tumour progression and poor prognosis after cisplatin treatment. We also found that DCTPP1 located in oxidoreductase complex and may be involved in various biological processes related to cisplatin resistance, including pyrimidine nucleotide metabolism, the P53 signalling pathwa...
Source: J Cell Mol Med - April 30, 2024 Category: Molecular Biology Authors: Yu Wang Xiangyun Chen Qiduan Chen Tiancai Liu Yingsong Wu Liping Huang Yao Chen Source Type: research
Expression of human dCTP pyrophosphatase 1 (DCTPP1) and its association with cisplatin resistance characteristics in ovarian cancer
In this study, we aimed to understand the role of DCTPP1 in cancer progression and cisplatin response. Using publicly available databases, we analysed the expression and clinical significance of DCTPP1 in ovarian cancer. Our bioinformatics analysis confirmed that DCTPP1 is significantly overexpressed in ovarian cancer and is closely associated with tumour progression and poor prognosis after cisplatin treatment. We also found that DCTPP1 located in oxidoreductase complex and may be involved in various biological processes related to cisplatin resistance, including pyrimidine nucleotide metabolism, the P53 signalling pathwa...
Source: Molecular Medicine - April 30, 2024 Category: Molecular Biology Authors: Yu Wang Xiangyun Chen Qiduan Chen Tiancai Liu Yingsong Wu Liping Huang Yao Chen Source Type: research
Molecular Mechanisms and Roles of MiR-136-5p in Human Cancer and Other Disorders
CONCLUSION: The current review aims to elucidate the role of miR-136-5p in both cancer progression and non-cancerous disorders, emphasizing dysregulated signaling pathways. It also sheds light on the potential of this miRNA as a prognostic biomarker in cancer, offering valuable insights and directions for future research.PMID:38685774 | DOI:10.2174/0109298673283936240215110627 (Source: Current Medicinal Chemistry)
Source: Current Medicinal Chemistry - April 30, 2024 Category: Chemistry Authors: Xiaoling Chen Ting Lu Ying Zheng Zhiyong Lin Chaoqi Liu Ding Yuan Chengfu Yuan Source Type: research
Integrative proteomic and transcriptomic analysis in the female goat ovary to explore the onset of puberty
This study conducted the first transcriptomic and proteomic correlation analysis of pre-pubertal and pubertal goat ovaries and identified six significantly correlated molecules at both the gene and protein levels. Meanwhile, we were drawn to several molecules and signalling pathways that may play a regulatory role in the onset of puberty and reproduction by influencing reproductive-related gene expression, GnRH receptor signals, energy metabolism, ovarian hormone secretion, follicular development, and ovulation. This information contributed to identify potential biomarkers in pubertal goat ovaries, which was vital for pred...
Source: Journal of Proteomics - April 30, 2024 Category: Biochemistry Authors: Ping Qin Zhihao Pan Wei Zhang Rui Wang Xiaoqian Li Juntai Lu Shuangshuang Xu Xinbao Gong Jing Ye Xu Yan Ya Liu Yunsheng Li Yunhai Zhang Fugui Fang Source Type: research
Treating Benign Ovarian Lesions in the Pediatric Population: A Single Institution's Retrospective Investigation of Laparoscopy Versus Open Repair
Conclusions: Laparoscopic surgery was performed for smaller lesions and was associated with a shorter length of hospital stay. Laparoscopic and OSS was found to have no increased risk of developing metachronous lesions nor increased reoperative risk compared with traditional open and oophorectomy techniques.PMID:38686518 | DOI:10.1089/lap.2023.0364 (Source: Adv Data)
Source: Adv Data - April 30, 2024 Category: Epidemiology Authors: Nicole Chicoine Niloufar Hafezi Victoria Sanchez Victoria Elliott Brian Gray Source Type: research
Exposure to the phthalate metabolite MEHP impacts survival and growth of human ovarian follicles in vitro
Toxicology. 2024 Apr 27:153815. doi: 10.1016/j.tox.2024.153815. Online ahead of print.ABSTRACTPhthalates are found in everyday items like plastics and personal care products. There is an increasing concern that continuous exposure can adversely affect female fertility. However, experimental data are lacking to establish causal links between exposure and disease in humans. To address this gap, we tested the effects of a common phthalate metabolite, mono-(2-ethylhexyl) phthalate (MEHP), on adult human ovaries in vitro using an epidemiologically determined human-relevant concentration range (2.05nM - 20.51mM). Histomorphologi...
Source: Toxicology - April 30, 2024 Category: Toxicology Authors: Eleftheria Maria Panagiotou Anastasios Damdimopoulos Tianyi Li Elisabeth Moussaud-Lamodi ère Mikael Pedersen Filipa Lebre Karin Pettersson Catarina Arnelo Kiriaki Papaikonomou Ernesto Alfaro-Moreno Cecilia Lindskog Terje Svingen Pauliina Damdimopoulou Source Type: research
Bioequivalence of Related GelShield < sup > Ⓡ < /sup > Sustained-Release Formulations of Metformin: A Pooled Pharmacokinetic Analysis
Clin Ther. 2024 Apr 29:S0149-2918(24)00077-8. doi: 10.1016/j.clinthera.2024.03.011. Online ahead of print.ABSTRACTPURPOSE: GlucophageⓇ (Merck Healthcare KGaA, Darmstadt, Germany) is the originator brand of metformin hydrochloride, an oral antidiabetic drug. Metformin is recommended in guidelines as first-line treatment of type 2 diabetes mellitus and increasingly in related insulin-resistant conditions, such as prediabetes and polycystic ovary syndrome. The GelShieldⓇ sustained-release formulation tablet of GlucophageⓇ has been improved from the historic version marketed in 2000. Bioequivalence has been demonstrated ...
Source: Clinical Therapeutics - April 30, 2024 Category: Drugs & Pharmacology Authors: Axel Krebs-Brown Kerstin M G Brand Marco A F Nogueira Filho Sumedh Gaikwad Yvonne Schnaars Source Type: research
Clinical and genomic landscape of RAS mutations in gynecologic cancers
CONCLUSION: RAS mutations in gynecologic cancers have a distinct histopathologic distribution and may impact overall survival. PIK3CA, PTEN, and ARID1A are potentially actionable co-alterations. RAS pathway-targeted therapy should be considered.PMID:38687597 | DOI:10.1158/1078-0432.CCR-23-2819 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - April 30, 2024 Category: Cancer & Oncology Authors: Ji Son Yingao Zhang Heather Lin Oriol Mirallas Pablo Alvarez Ballesteros Mirella Nardo Natalie Clark R Tyler Hillman Erick Campbell Vijaykumar Holla Amber M Johnson Amadeo B Biter Ying Yuan Lauren P Cobb David M Gershenson Amir A Jazaeri Karen H Lu Pamela Source Type: research
Deciphering resistance mechanisms and novel strategies to overcome drug resistance in ovarian cancer: a comprehensive review
Oncol Res. 2024 Apr 23;32(5):831-847. doi: 10.32604/or.2024.031006. eCollection 2024.ABSTRACTOvarian cancer is among the most lethal gynecological cancers, primarily due to the lack of specific symptoms leading to an advanced-stage diagnosis and resistance to chemotherapy. Drug resistance (DR) poses the most significant challenge in treating patients with existing drugs. The Food and Drug Administration (FDA) has recently approved three new therapeutic drugs, including two poly (ADP-ribose) polymerase (PARP) inhibitors (olaparib and niraparib) and one vascular endothelial growth factor (VEGF) inhibitor (bevacizumab) for ma...
Source: Oncology Research - April 30, 2024 Category: Cancer & Oncology Authors: Effat Alemzadeh Leila Allahqoli Afrooz Mazidimoradi Esmat Alemzadeh Fahimeh Ghasemi Hamid Salehiniya Ibrahim Alkatout Source Type: research
Expression of human dCTP pyrophosphatase 1 (DCTPP1) and its association with cisplatin resistance characteristics in ovarian cancer
In this study, we aimed to understand the role of DCTPP1 in cancer progression and cisplatin response. Using publicly available databases, we analysed the expression and clinical significance of DCTPP1 in ovarian cancer. Our bioinformatics analysis confirmed that DCTPP1 is significantly overexpressed in ovarian cancer and is closely associated with tumour progression and poor prognosis after cisplatin treatment. We also found that DCTPP1 located in oxidoreductase complex and may be involved in various biological processes related to cisplatin resistance, including pyrimidine nucleotide metabolism, the P53 signalling pathwa...
Source: J Cell Mol Med - April 30, 2024 Category: Molecular Biology Authors: Yu Wang Xiangyun Chen Qiduan Chen Tiancai Liu Yingsong Wu Liping Huang Yao Chen Source Type: research
Expression of human dCTP pyrophosphatase 1 (DCTPP1) and its association with cisplatin resistance characteristics in ovarian cancer
In this study, we aimed to understand the role of DCTPP1 in cancer progression and cisplatin response. Using publicly available databases, we analysed the expression and clinical significance of DCTPP1 in ovarian cancer. Our bioinformatics analysis confirmed that DCTPP1 is significantly overexpressed in ovarian cancer and is closely associated with tumour progression and poor prognosis after cisplatin treatment. We also found that DCTPP1 located in oxidoreductase complex and may be involved in various biological processes related to cisplatin resistance, including pyrimidine nucleotide metabolism, the P53 signalling pathwa...
Source: Molecular Medicine - April 30, 2024 Category: Molecular Biology Authors: Yu Wang Xiangyun Chen Qiduan Chen Tiancai Liu Yingsong Wu Liping Huang Yao Chen Source Type: research
